BMJ Oncology Editorial Board members have agreed and adhere to the BMJ Editor Roles and Responsibilities guidelines; including our Editor policy on competing interests. Meet the editorial team.
Ananya Choudhury, MA (Cantab), PhD, MRCP, FRCR Chair and Honorary Consultant in Clinical Oncology Group Leader Translational Radiobiology The Christie NHS Foundation Trust Manchester, United Kingdom Declaration of Interests, see here
Professor Choudhury is Chair and Honorary Consultant in Clinical Oncology. She joined The Christie in 2008 specializing in urology and sarcoma and has a strong interest in translational research. In 2013, she decided to focus on radiotherapy-related research in prostate and bladder cancers. She is clinical lead for advanced radiotherapy including the MRLinac project and is co-Group Leader of The Translational Radiobiology Group within the Division of Cancer Sciences. Professor Choudhury currently undertakes research which aims to optimize and personalize radiotherapy using new techniques or imaging technology to deliver high doses of radiotherapy while minimizing side effects and predictive biomarkers to determine which patients benefit from different treatments. Professor Choudhury formerly served as Editor-In-Chief of Clinical Oncology, the official journal of The Royal College of Radiologists. In addition, Professor Choudhury was a Senior Editor for Genito-urinary cancers for the International Journal of Radiation Oncology • Biology • Physics (The Red Journal). Although coming from a radiotherapy specialist area, Professor Choudhury is passionate about all aspects of general oncology. Editorially, Professor Choudhury advocates equality and diversity in research and publication and promotes partnership with patients and the public.
Kristoffer Stewart BMJ London, United Kingdom
Kristoffer is a UK-trained pharmacist working in education and publishing. His education interest has focused on general practice and early career practitioners. Kristoffer has worked with BMJ Best Practice, BMJ Learning and The Pharmaceutical Journal. Kristoffer is excited to work on BMJ Oncology and to develop a dynamic cross-disciplinary editorial board to attract the best research, reviews and editorials.
Editorial Board Members
Jeena Ackroyd Calderdale Royal Hospital West Yorkshire, UK
Jeena Ackroyd is a Consultant in Palliative Medicine in Calderdale West Yorkshire. She has a Masters in the Ethics of Cancer and Palliative care and is a member of the local clinical ethics committee and nationally is the palliative care representative for the NICE metastatic spinal cord compression updated guidelines committee. Research focus: Complex decision making in cancer patients, especially around end of life care. Supportive interventions for haematology patients and mentoring for clinicians.
Melvin Lee Kiang Chua National Cancer Centre Singapore Singapore
Dr Chua, MBBS, FRCR, PhD, FAMS is a Clinician-Scientist at the National Cancer Centre Singapore (NCCS) and Duke-NUS Medical School, and Principal Investigator of the Precision Radiotherapeutics and Oncology Programme, Division of Medical Sciences, supported by the NMRC Clinician-Scientist Award. He is also the Head of Department and Senior Consultant for Head and Neck and Thoracic Cancers, Division of Radiation Oncology, and Director of the Data and Computational Science Core at the NCCS. Research focus: His research focuses on the development of Phase II-III clinical trials in nasopharyngeal (NPC) and prostate cancers. He also runs a laboratory that is involved in data science and omics analytics that help with therapeutic and biomarker discovery for these cancer types.
Bishal Gyawali Queen's University Ontario, Canada
Bishal Gyawali, MD, PhD is a medical oncologist and an associate professor in medical oncology and public health sciences and scientist in the Division of Cancer Care and Epidemiology, in Queen’s University, Kingston, Canada. He did his cancer policy fellowship at Harvard Medical School and previously served as a medical consultant for the not-for-profit Anticancer Fund, before joining Queen’s. His clinical expertise is across multiple adult solid tumors, with special focus on GI, GU and breast malignancies. Dr. Gyawali is an expert for the WHO Drug Advisory Panel. He is a member of the WHO Essential Medicines List Committee for cancer drugs, ESMO-Magnitude of Clinical Benefit Scale and ESMO Global Policy committees, and ASCO-Health Equity and Outcomes Committee. Research focus: Dr. Gyawali’s areas of academic interests include cancer policy, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, supportive care, cancer care disparities, and global oncology. He introduced the term “cancer groundshot” and chaired a session on the same at ASCO 2022. His interviews and studies have been reported in several influential media (e.g. CNN, NPR, Washington Post, STAT News etc). ORICD: https://orcid.org/0000-0001-7444-8594
Laure Marignol Trinity College Dublin, Ireland
Laure Marignol is an associate professor and the Head of Discipline of Radiation Therapy at Trinity College Dublin, Ireland. She leads an internationally recognised radiobiology laboratory. Laure is an active member within the radiobiology international community. She holds a leadership position within the Irish Radiation Research Society and sits on the Radiobiology Committee of the European Society for Radiotherapy and Oncology (ESTRO). She serves as specialist examiner for Royal College of Radiologists in the UK. Research focus: Dr Marignol’s lab aims to generate new prognostic algorithms that detect patients at high risk of failure following radiation therapy, and design new therapeutic options that prevent tumour regrowth after radiotherapy. She has published works aimed at addressing the international challenge of growing solutions for the optimal destruction of cancer cells. ORICD: https://orcid.org/0000-0002-2680-6200
Vedang Murthy Tata Memorial Centre Mumbai, India
Vedang Murthy is a Professor of Radiation Oncology at Tata Memorial Centre, Mumbai. Dr. Murthy also trained at The Royal Marsden NHS Foundation Hospital, London and undertook a Diploma in Epidemiology and Biostatistics from the London School of Health and Tropical Medicine. Dr Murthy is the Convenor of Uro Oncology Disease Management group at the Tata Memorial Hospital and currently running investigator-initiated randomised trials in prostate and bladder cancer. Research focus: Stereotactic Body Radiation Therapy and Pelvic Radiation Therapy for high risk prostate cancer, prostate-specific membrane antigen positron emission tomography (PSMA PET) in Prostate cancer, bladder preservation and adjuvant radiotherapy in bladder cancer and radiotherapy in seminoma and advanced penile cancers.
Dr. Miriam Mutebi is a Consultant Breast Surgical Oncologist and Assistant Professor of Surgery at the Aga Khan University in Nairobi, Kenya. She is also a clinical epidemiologist and health systems researcher. She is the President Elect of the African Organization for Research and Training in Cancer (AORTIC), the immediate past president for the Kenya Society of Hematology and Oncology (KESHO) and on the board of directors of the Union for International Cancer Control (UICC). She is the Co-chair of the National Cancer Taskforce in Kenya, Chair of the Commonwealth Taskforce for the elimination of Cervical Cancer and a commissioner on five Lancet commissions including Breast Cancer, Women and Cancer and Cancer in sub-Saharan Africa etc. Research focus: Her focus is on on understanding barriers to access for women with cancers in Africa and in designing interventions to mitigate those barriers, health systems strengthening, health policy and cancer disparities.
Eliana Vasquez Osorio University of Manchester Manchester, UK
Dr Vasquez Osorio studied computer sciences at the Universidad EAFIT, Medellin Colombia. She then did her PhD at Erasmus University in Rotterdam, The Netherlands and is currently a senior research fellow at the University of Manchester. Research focus: Her areas of expertise include image processing, non-rigid image registration, computational geometry, deformation modelling and treatment outcome modelling. She also works with artificial intelligence techniques to solve radiotherapy problems.
Richard Simcock University Hospital Sussex Sussex, UK
Richard Simcock MRCPI FRCR is a Consultant Clinical Oncologist at University Hospital Sussex NHS Trust and Honorary Professor at Brighton and Sussex Medical Schools. He is Chief Medical Officer at Macmillan Cancer Support where he co-leads the Centre of Clinical Expertise. Research focus: Research and training on communication, shared decision making. Free open access medical education via social media. Interested in improving the care of the older adult with cancer including the assessment and management of frailty and multimorbidity. Planning and delivery of personalised care and innovative workforce solutions are current preoccupations ORCID: https://orcid.org/0000-0002-9828-4114
Tsang Yat Princess Margaret Cancer Center Ontario, Canada
Currently, Yat Tsang is employed as the Director of Radiation Therapy within the Radiation Medicine Program at the Princess Margaret Cancer Center under University Health Network in Canada. He is a senior member of the UK National Institute of Health Research (NIHR) Radiotherapy Trials QA Group with experience in designing and implementing quality assurance programmes for NIHR clinical trials. Being the Chair of the European society for radiotherapy and oncology Radiation Therapist Committee, Yat is accountable for leading and organising international radiotherapy specific projects Research focus: Radiotherapy trial quality assurance, ultra-hypofractionated/ stereotactic radiotherapy treatment outcomes, and strategies to future-proofing radiation therapist practice.
Statistical Editorial Board
Allan Hackshaw University College London Cancer Research UK & UCL Cancer Trials Centre London, UK
Allan Hackshaw is Professor of Epidemiology & Medical Statistics at University College London, and Director of the Cancer Research UK & UCL Cancer Trials Centre, one of the largest cancer trials units in the UK. Previously, he was at the Wolfson Institute of Environmental and Preventive Medicine, Barts, London. Research focus: He has >30 years’ experience in the design, conduct and interpretation of phase I-III clinical trials, observational studies, real world data studies and systematic reviews, in a variety of disease areas; including cancer treatments and diagnosis, adult and prenatal screening, cardiovascular disease, and tobacco and health. He has worked in several cancer types (notably lung, thyroid, breast and gynaecological) and all types of interventions (systematic therapies including targeted and immunotherapies, radiotherapy, surgery, and combinations of them). He has published more than 200 journal articles and book chapters, and sole or first author of four textbooks, including two on clinical trials. He delivers modules on evidence-based medicine and clinical trials for postgraduate courses at UCL and the London School of Economics. ORCID: https://orcid.org/0000-0002-5570-5070
Amy Kirkwood University College London London, UK
Amy Kirkwood is an Associate Professor in Medical Statistics at the CRUK and UCL Cancer Trials Centre. She was worked in cancer trials for almost 15 years, including all phases and covering a range of interventions. Research focus: She specialises in haematological malignancy trials, with a particular interest in Hodgkin’s lymphoma and acute lymphoblastic leukaemia”.
Andre Lopes University College London, UK
Andre Lopes is an Associate Professor in Medical Statistics at the CRUK & UCL Cancer Trials Centre. Research focus: His research interests are focused on the design of early and late phase cancer clinical trials, in particular gastrointestinal, sarcoma, and CAR-T cell therapies. He also has special interests in health outcomes in cancer research including health-related quality of life and disease stabilisation, and joint survival and longitudinal analyses
Publisher: Catherine Dolinsky Head of Portfolio: Kathleen Lyons